Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 33-42

  Medina, Oula Penate ^a,e   Kairemo, Kalevi ^a,d,e   Valtanen, Heli ^a,e   Kangasniemi, Aino ^a   Kaukinen, Sami ^a,e   Ahonen, Ilona ^b   Permi, Perttu ^b   Annila, Arto ^b   Sneck, Mia ^a   Holopainen, Juha M ^c   Karonen, Sirkka Liisa ^d   Kinnunen, Paavo K J ^c   Koivunen, Erkki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Helsinki Biophys and Biomemb Grp   (Canada)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Cancer Targeting Technologies Oy   (Finland)

Author keywords

Angiogenesis; Imaging; Liposomes; Matrix metalloproteinases; Phage display

Indexed keywords

CYSTEINYLTHREONYLTHREONYLHISTIDYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLLEUCYL CYSTEINE; GELATINASE; GELATINASE INHIBITOR; IODINE 125; LIPOSOME; RADIOISOTOPE; SYNTHETIC PEPTIDE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER; CANCER LOCALIZATION; CANCER MODEL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DISTRIBUTION; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; KIDNEY CLEARANCE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCINTILLATION CAMERA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; FIBROSARCOMA; HUMANS; IODINE RADIOISOTOPES; LIPOSOMES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PEPTIDES, CYCLIC; PROTEASE INHIBITORS; RADIOPHARMACEUTICALS; SARCOMA, KAPOSI; TECHNETIUM; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 20144386646     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Duffy MJ: PSA as a marker for prostate cancer. Ann Clin Biochem 33: 511-19, 1996.
2. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS and McCarthy D: W. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nuclear Med 42: 213-21, 2001.
3. Pegram MD and Reese DM: Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Seminars Oncol 29(Suppl. 11): 29-37, 2002.
4. Chang SS, Bander NH and Heston WD: Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen? Curr Opinion Urol 9: 391-95, 1999.
5. Pasqualini R and Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature 380: 364-66, 1996.
6. Arap W, Pasqualini R and Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-80, 1998.
7. Laakkonen P, Porkka K, Hoffman J A and Ruoslahti E: A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8: 751-55, 2002.
8. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind L M, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ and Pasqualini R: Steps toward mapping the human vasculature by phage display. Nat Med 8: 121-27, 2002.
9. Koivunen E, Arap W, Valtanen E, Rainisalo A, Medina OP, Heikkilä P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E and Pasqualini R: Tumor targeting with a selective gelatinase inhibitor Nat Biotechnol 17: 768-74, 1999.
10. 3. Cell 85: 683-93, 1996.
11. Nguyen M, Arkell J and Jackson C J: Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 33: 960-70, 2001.
12. Swallow CJ, Murray MP and Guillem JG: Metastatic colorectal cancer cells induce matrix metalloproteinase release by human monocytes. Clin Exp Metastasis 14: 3-11, 1996.
13. Saad S, Gottlieb DJ, Bradstock K, Overall CM and Bendall LJ: Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts Cancer Res 62: 283-89, 2002.
14. Bremer C, Tung CH and Weissleder R: In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7: 743-48, 2001.
15. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-74, 2002.
16. Pozzi A, LeVine W F and Gardner H: Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21: 272-82, 2002.
17. Medina OP, Söderlund T, Laakkonen LJ, Tuominen EKJ, Koivunen E and Kinnunen PKJ: Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res 61: 3978-85, 2001.
18. Braunschweiler L and Ernst RR: Coherence transfer by isotropic mixing - application to proton correlation spectroscopy. J Magn Reson 53: 521-28, 1983.
19. Kumar A, Ernst RR and Wuthrich KA: Two-dimensional nuclear overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem Biophys Re Commun 95: 1-6, 1980.
20. Cavanagh J and Ranee M: Suppression of cross-relaxation effects in TOCSY spectra via a modified DIPSI-2 mixing sequence. J Magn Reson 96: 670-78, 1992.
21. John BK, Plant and Hurd RE: Improved proton-detected heteronuclear correlation using gradient-enhanced z and zz-filters. J Magn Reson A101: 113-17, 1992.
22. Günthert P, Mumenthaler C and Wütrich K: Torsion angle dynamics for NMR structure calculation with the new program DYANA. J Mol Biol 273: 283-98, 1997.
23. Zalutsky MR, Noska MA, Colapinto EV, Garg PK and Bigner DD: Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. Cancer Res 49: 5543-49, 1989.
24. Clifford CJ, Warren EL, Richard TW and Pfeiffer DR: Factors affecting solute entrapment in phospholipid vesicles prepared by the freeze-thaw extrusion method: a possible general method for improving the efficiency of entrapment. Chem Phys Lipids 55: 73-83, 1990.
25. MacDonald RC, MacDonald RI, Menco BM, Takeshita K, Subbarao NK and Hu LR: Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1061: 297-303, 1991.
26. George AJT, Jamar F, Tai M, Heelan BT, Adams GP, McCartney JE, Houston LL, Weiner LM, Opeprmann H, Peters AM and Huston JS: Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci 92: 8358-62, 1995.
27. Van Regenmortel MHV and Muller S: D-peptides as immunogens and diagnostic reagents. Curr Opin Biotechnol 9: 377-82, 1998.
28. Björklund M, Valtanen H, Savilahti H and Koivunen E: Use of intern-directed peptide biosynthesis to improve serum stability and bioactivity of a gelatinase inhibitory peptide. Comb Chem High Throughput Screen 6: 29-35, 2003.